K2 Principal Fund, L.P. Pharma Cyte Biotech, Inc. Transaction History
K2 Principal Fund, L.P.
- $285 Million
- Q1 2024
A detailed history of K2 Principal Fund, L.P. transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 327,503 shares of PMCB stock, worth $684,481. This represents 0.27% of its overall portfolio holdings.
Number of Shares
327,503
Previous 304,613
7.51%
Holding current value
$684,481
Previous $657,000
18.11%
% of portfolio
0.27%
Previous 0.14%
Shares
8 transactions
Others Institutions Holding PMCB
# of Institutions
32Shares Held
1.07MCall Options Held
5.4KPut Options Held
400-
Geode Capital Management, LLC Boston, MA200KShares$418,5870.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA175KShares$364,9180.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$192,4617.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$172,8990.12% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny43.8KShares$91,5420.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $43.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...